Acucela presented new safety, tolerability and effectiveness data on ACU-4429, an investigational therapy for dry age-related macular degeneration (AMD), at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held this week in Fort Lauderdale, Florida. Study participants...
Acucela Presents Dry AMD Therapy Data At ARVO
Tear Research Focused On Contact Lens Risks, Benefit
Contact lenses are great for sight, but do they have an impact on general eye health? Researchers at the University of Alabama at Birmingham (UAB) School of Optometry are working to answer that question by analyzing tears. Biological changes in the eye can be measured through minor fluctuations in the...
Alimera Sciences Announces Presentation Of Data From The 12-Month Interim Readout Of The Human PK Iluvien(TM) Study At ARVO 2009 Annual Meeting
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study)...
Fovea Reports Positive Results With Prednisporin(TM) In Persistent Allergic Conjunctivitis
Fovea Pharmaceuticals announced positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better safety profile (no increase in intra-ocular...
$1.48 Million To Study LASIK Complictions Awarded To K-State Professor
Gary Conrad, a university distinguished professor at Kansas State University’s Division of Biology, has received a four-year grant renewal of $1.48 million from The National Eye Institute of the National Institutes of Health to study the cornea. “The NIH renewal will make Conrad’s grant...
Bionic Eye Expected By 2011 In Australia
The first clinical test of an Australian bionic eye is likely to take place within two years and be commercialised within five according to University of Melbourne researchers, thanks to a $50 million funding boost from the Federal Government. Director of Bionic Vision Australia and Professor of Engineering...
Etrials Chosen By MacuSight As Its EDC And IVR Solutions Provider On Three Ophthalmology Studies
etrials Worldwide, Inc. (NASDAQ:ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, announced that MacuSight Inc., has selected etrials’ Trial...
Inhaled And Oral Steroid Use Impacts Cataract Risk
A study conducted by the Centre for Vision Research, University of Sydney, Australia, examines how steroid (corticosteroid) use relates to risks for cataract,b the clouding of the eye’s lens that leads to reduced vision and blindness, if untreated. Many people with asthma rely on inhaled, and sometimes...
Young Eye Researchers Receive Prestigious ARVO-AFER/Merck Award
Four researchers under age 45 have been named as recipients of the 2009 ARVO-AFER/Merck Innovative Ophthalmology Research Award (IORA) for their work in glaucoma and back-of-the-eye diseases. The awards are worth a total of $70,000 for the researchers and their laboratories. The IORA - made possible...
Glaucoma Mystery Solved By Genetic Sleuth
Dr. Michael Walter is one good gumshoe. The University of Alberta medical geneticist has cracked the case of WDR36, a gene linked to glaucoma. Glaucoma is a leading cause of blindness in which cells in the optic nerve die, preventing the brain from understanding what patients see. Scientists have long...